Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors.
Aged
Aged, 80 and over
Biopsy
Cross-Over Studies
Docetaxel
/ administration & dosage
Drug Carriers
/ chemistry
Drug Liberation
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Nanoparticles
/ chemistry
Neoplasms
/ drug therapy
Neutropenia
/ blood
Response Evaluation Criteria in Solid Tumors
Tissue Distribution
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2020
15 07 2020
Historique:
received:
02
01
2020
revised:
09
03
2020
accepted:
15
04
2020
pubmed:
24
4
2020
medline:
3
11
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
CPC634 is a novel nanoparticle entrapping docetaxel, developed to enhance the intratumoral chemotherapy exposure. This randomized cross-over study compared the intratumoral and plasma pharmacokinetics of CPC634 with conventional docetaxel. Adult patients with solid tumors were randomized to receive CPC634 (75 mg/m In total, 24 evaluable patients were included. In the tumor, CPC634 exhibited a 461% higher total docetaxel ( Here, we demonstrated that CPC634 enhanced the intratumoral total docetaxel exposure compared with conventional docetaxel. The lower incidence of neutropenia during CPC634 treatment is presumably related to lower plasma
Identifiants
pubmed: 32321718
pii: 1078-0432.CCR-20-0008
doi: 10.1158/1078-0432.CCR-20-0008
doi:
Substances chimiques
Drug Carriers
0
Docetaxel
15H5577CQD
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3537-3545Informations de copyright
©2020 American Association for Cancer Research.